HARBIN, China, Aug. 16, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (CBP.) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that the Company has recently been named a "High Integrity Enterprise" at the 2nd Session of Heilongjiang Pharmaceutical Integrity Enterprise Selection Committee ("the Committee"), which includes members from the local government and trade associations, including the Heilongjiang Integrity Promotion Association, the Heilongjiang Food and Drug Administration, and the Heilongjiang Pharmaceutical Industry Association.

The Committee's goal is to promote business ethics and integrity in the regional pharmaceutical industry, with its nominees serving as examples of honesty and trustworthiness. The Committee advocates the principles of "integrity in production" and "integrity in management". The promotion of ethical standards is intended to provide a solid foundation of trust for the Heilongjiang pharmaceutical industry. Each candidate company is evaluated separately by the provincial Administration of Industry and Commerce, Tax Administration, Food and Drug Administration and the Committee. The finalist is awarded the "High Integrity Enterprise" title after public consent.

"We are in the business of providing all-natural plant based remedies. Our products reflect high-quality standards and are produced keeping our customers good health in perspective. Similarly, we apply the principles of honesty and integrity in our business operations as well. We are pleased to be named as a 'High Integrity Enterprise' in Heilongjiang Province and would like to thank our employees for all their dedication," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We are encouraged and rewarded by our customers who trust us to provide them with only the finest plant-based ingredients. We believe this award is an honor and a testament to the all-natural plant based solutions we deliver."

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.

China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

Company Contact:
China Botanic Pharmaceutical Inc.
Ms. Portia Tan, IR Contact
Tel: +86-451-8260-2162
Email: ir@renhuang.com
 

 
CCG Investor Relations:
Mr. Mark Collinson, Partner
Phone: +1-310-954-1343 (Los Angeles)
Email: mark.collinson@ccgir.com
Website: www.ccgirasia.com
 

 
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com